Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of “Buy” from Brokerages

Immunic, Inc. (NASDAQ:IMUX) has been given a consensus rating of “Buy” by the nine research firms that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $12.67.

A number of research firms have weighed in on IMUX. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. William Blair initiated coverage on Immunic in a research note on Tuesday. They issued an “outperform” rating on the stock. D. Boral Capital reissued a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Wednesday, February 26th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Immunic in a report on Friday, February 21st.

Immunic Price Performance

IMUX stock opened at $1.24 on Friday. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11. The firm has a 50-day moving average of $1.08 and a 200 day moving average of $1.21. The company has a market cap of $111.70 million, a P/E ratio of -1.01 and a beta of 1.89.

Institutional Investors Weigh In On Immunic

Several hedge funds have recently added to or reduced their stakes in the stock. State Street Corp raised its position in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the last quarter. 683 Capital Management LLC increased its stake in Immunic by 2.2% during the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after purchasing an additional 15,349 shares in the last quarter. Bridgeway Capital Management LLC raised its holdings in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after buying an additional 22,200 shares during the last quarter. Focus Partners Wealth lifted its stake in shares of Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after buying an additional 23,610 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Immunic during the third quarter valued at approximately $50,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.